TORONTO, ONTARIO -- (Marketwire) -- 01/24/13 -- Biologix Hair Inc. (OTCBB: TGPO) (OTCQB: TGPO) has appointed Dr. Diego Castresana to Vice President of Research and Development and a member of the Company's Board of Directors. In addition to today's appointments, Dr. Castresana continues to serve as Vice President of Research and Development for Biologix Hair Science Ltd., the wholly owned subsidiary of Biologix Hair Inc., which controls the worldwide Intellectual Property rights associated with the Biologix Hair Therapy System.
Diego Castresana, MD, Ms. H.S.A., is a physician from Universidad del Norte in Barranquilla, Colombia, having obtained his degree in 1993. He attained a Master's degree in Health Services Administration from Nova Southeastern University in 1999 and a certificate in Top Management from Universidad del Norte in 2004.
Dr. Castresana worked for Universidad del Norte as a graduate studies professor, Director of Graduate Programs in Health Services Administration, a hospital board member and as CEO of the university hospital, where he led the process of transforming it from a basic healthcare center to a state-of-the-art university hospital with high-level complexity. In 2005 Diego Castresana moved to Cuenca, Ecuador to work for American Hospital Management Company as CEO of Hospital Universitario del Rio, the largest university hospital in the south of the country. Dr. Castresana was appointed CEO when the new facility was 45% built and directed all of the activities oriented towards completion of two buildings, occupying 37,000 m(2 ) with state-of-the-art medical equipment and serving an area equal to one-fourth of the country. Following this success he became a private consultant for the healthcare sector in Barranquilla.
Dr. Castresana stated, "Research and development at Biologix Hair Inc. is extremely important. The work we are already doing with the Beijing Institute of Technology to standardize our patent pending Biologix Revive hair formula also has the potential to uncover refinements and I look forward to learning both exciting new information about alopecia as well as potential ways in which we can continuously improve our already remarkably effective therapy. I am pleased that R&D is an ongoing priority for Biologix and honored to lead this effort as we work towards securing worldwide approvals for the Biologix Hair Therapy System."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Allstate Seeks to Invest in Minority Firms
- SpaceX's Satellite Launch Is 'Game-Changer'
- Latin Music Conference Turns 25
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Newtown Massacre Heard on 911 Recordings
- Climate Change Early Warning System Urged
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Reid Confident Congress to Pass Immigration Bill